Hologic HOLX posted Diagnostics revenues of $464.4 million in the first quarter of fiscal 2026, down 1.3% from last year. The segment remains anchored by the molecular diagnostic assays, which run on ...

Shares of Hologic HOLX closed the first trading session of the year at $74.56, which is quite close to the 52-week high of $75.34, reached on Dec. 15, 2025. In the past six months, the company has ...

New Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays deliver tailored, actionable diagnostic results to support fast and informed patient care A variety of complex factors, ...

Hologic HOLX has highlighted the role of its Panther Fusion platform in supporting the future growth of its Diagnostics business. Fusion is an add-on module to the base Panther system, providing a ...

Hologic HOLX offers a wide range of diagnostic products to help in the screening and diagnosis of human disease. Although the performance of the Diagnostics segment in recent quarters has been ...